Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA5A | P35218 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964436 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL25592597 | 0.83 | ALDH1A1 (0.62) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL9349723 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL11133671 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL11809314 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL219209 | 0.77 | ALDH1A1 (0.80) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL11129758 | 0.76 | CA1 (0.41) | ALDH1A1CA2CA1CA9CA3 | |
| SCHEMBL11815362 | 0.75 | ALDH1A1 (0.51) | ALDH1A1CYP3A4POLBHTTCTSB | |
| Nitrogen SCHEMBL28796026 | 0.74 | ALDH1A1 (0.74) | ALDH1A1CYP3A4POLBHTTCTSB | |
| SCHEMBL29973143 | 0.73 | ALDH1A1 (0.67) | ALDH1A1CYP3A4POLBHTTCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| EP-3151818-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | Case Western Reserve University (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | ALDH1A1 607/4885CYP3A4 4631/4885POLB 2022/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | ALDH1A1 2397/4885CYP3A4 1389/4885POLB 4633/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | ALDH1A1 647/4885CYP3A4 4809/4885POLB 3236/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | ALDH1A1 647/4885CYP3A4 4809/4885POLB 3236/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | ALDH1A1 2397/4885CYP3A4 1389/4885POLB 4633/4885 |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | ALDH1A1 2397/4885CYP3A4 1389/4885POLB 4633/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | ALDH1A1 245/4885CYP3A4 2194/4885POLB 2624/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | ALDH1A1 607/4885CYP3A4 4631/4885POLB 2022/4885 |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TYR, HRH2 | ALDH1A1 174/4885CYP3A4 1823/4885POLB 2151/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | ALDH1A1 245/4885CYP3A4 2194/4885POLB 2624/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | ALDH1A1 245/4885CYP3A4 2194/4885POLB 2624/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | ALDH1A1 245/4885CYP3A4 2194/4885POLB 2624/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | ALDH1A1 647/4885CYP3A4 4809/4885POLB 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.